APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Growth Hormone Deficiency (Ghd) Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Human Growth Hormone Deficiency (Ghd) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025190 pages

Choose your research edition.

Industry ResearchHuman Growth Hormone Deficiency (Ghd) Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Growth Hormone Deficiency (Ghd) Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Human Growth Hormone Deficiency (Ghd) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Growth Hormone Deficiency (Ghd) Drug Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Growth Hormone Deficiency (Ghd) Drug Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Human Growth Hormone Deficiency (Ghd) Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Human Growth Hormone Deficiency (Ghd) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Growth Hormone Deficiency (Ghd) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Growth Hormone Deficiency (Ghd) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Human Growth Hormone Deficiency (Ghd) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human Growth Hormone Deficiency (Ghd) Drug include Teva Pharmaceutical Industries, Ltd, Merck KGaA, Eli Lilly and Company, Versartis Inc., Strongbridge Biopharma, Sandoz International GmbH (Novartis AG), Pfizer Inc, Opko Health, Inc. and Novo Nordisk A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Growth Hormone Deficiency (Ghd) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Growth Hormone Deficiency (Ghd) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Growth Hormone Deficiency (Ghd) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Growth Hormone Deficiency (Ghd) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Growth Hormone Deficiency (Ghd) Drug Segment by Company

Teva Pharmaceutical Industries, Ltd

Merck KGaA

Eli Lilly and Company

Versartis Inc.

Strongbridge Biopharma

Sandoz International GmbH (Novartis AG)

Pfizer Inc

Opko Health, Inc.

Novo Nordisk A/S

LG Life Sciences

Ipsen S.A.

GeneScience Pharmaceuticals Co. Ltd

Genentech, Inc (Roche)

Ferring Pharmaceuticals

EMD Serono Inc.

Ascendis Pharma A/S

AnkeBio Co. Ltd

Human Growth Hormone Deficiency (Ghd) Drug Segment by Type

Somavaratan

Somapacitan

TransCon-hGH

Others

Human Growth Hormone Deficiency (Ghd) Drug Segment by Application

Children

Adults

Human Growth Hormone Deficiency (Ghd) Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Growth Hormone Deficiency (Ghd) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Growth Hormone Deficiency (Ghd) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Growth Hormone Deficiency (Ghd) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Growth Hormone Deficiency (Ghd) Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Growth Hormone Deficiency (Ghd) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Growth Hormone Deficiency (Ghd) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Growth Hormone Deficiency (Ghd) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Growth Hormone Deficiency (Ghd) Drug Industry Trends Table 2. Human Growth Hormone Deficiency (Ghd) Drug Industry Drivers Table 3. Human Growth Hormone Deficiency (Ghd) Drug Industry Opportunities and Challenges Table 4. Human Growth Hormone Deficiency (Ghd) Drug Industry Restraints Table 5. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Manufacturers Table 9. Global Human Growth Hormone Deficiency (Ghd) Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Human Growth Hormone Deficiency (Ghd) Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Growth Hormone Deficiency (Ghd) Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Growth Hormone Deficiency (Ghd) Drug Manufacturers, Product Type & Application Table 13. Global Human Growth Hormone Deficiency (Ghd) Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Growth Hormone Deficiency (Ghd) Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Somavaratan Table 17. Major Manufacturers of Somapacitan Table 18. Major Manufacturers of TransCon-hGH Table 19. Major Manufacturers of Others Table 20. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Type (2021-2026) & (K Units) Table 22. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Type (2027-2032) & (K Units) Table 23. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Type (2021-2026) Table 24. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Type (2027-2032) Table 25. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Type (2021-2026) & (K Units) Table 27. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Type (2027-2032) & (K Units) Table 28. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Type (2021-2026) Table 29. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Children Table 31. Major Manufacturers of Adults Table 32. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Application (2021-2026) & (K Units) Table 34. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Application (2027-2032) & (K Units) Table 35. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Application (2021-2026) Table 36. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Application (2027-2032) Table 37. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Application (2021-2026) & (K Units) Table 39. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Application (2027-2032) & (K Units) Table 40. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Application (2021-2026) Table 41. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Application (2027-2032) Table 42. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Region (2021-2026) Table 45. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Human Growth Hormone Deficiency (Ghd) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2026) & (K Units) Table 49. North America Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2027-2032) & (K Units) Table 50. Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2026) & (K Units) Table 52. Europe Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2027-2032) & (K Units) Table 59. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Region (2021-2026) Table 63. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Region (2027-2032) Table 64. Teva Pharmaceutical Industries, Ltd Company Information Table 65. Teva Pharmaceutical Industries, Ltd Business Overview Table 66. Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 68. Teva Pharmaceutical Industries, Ltd Recent Development Table 69. Merck KGaA Company Information Table 70. Merck KGaA Business Overview Table 71. Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 73. Merck KGaA Recent Development Table 74. Eli Lilly and Company Company Information Table 75. Eli Lilly and Company Business Overview Table 76. Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 78. Eli Lilly and Company Recent Development Table 79. Versartis Inc. Company Information Table 80. Versartis Inc. Business Overview Table 81. Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 83. Versartis Inc. Recent Development Table 84. Strongbridge Biopharma Company Information Table 85. Strongbridge Biopharma Business Overview Table 86. Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 88. Strongbridge Biopharma Recent Development Table 89. Sandoz International GmbH (Novartis AG) Company Information Table 90. Sandoz International GmbH (Novartis AG) Business Overview Table 91. Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 93. Sandoz International GmbH (Novartis AG) Recent Development Table 94. Pfizer Inc Company Information Table 95. Pfizer Inc Business Overview Table 96. Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 98. Pfizer Inc Recent Development Table 99. Opko Health, Inc. Company Information Table 100. Opko Health, Inc. Business Overview Table 101. Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 103. Opko Health, Inc. Recent Development Table 104. Novo Nordisk A/S Company Information Table 105. Novo Nordisk A/S Business Overview Table 106. Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 108. Novo Nordisk A/S Recent Development Table 109. LG Life Sciences Company Information Table 110. LG Life Sciences Business Overview Table 111. LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 113. LG Life Sciences Recent Development Table 114. Ipsen S.A. Company Information Table 115. Ipsen S.A. Business Overview Table 116. Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 118. Ipsen S.A. Recent Development Table 119. GeneScience Pharmaceuticals Co. Ltd Company Information Table 120. GeneScience Pharmaceuticals Co. Ltd Business Overview Table 121. GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 123. GeneScience Pharmaceuticals Co. Ltd Recent Development Table 124. Genentech, Inc (Roche) Company Information Table 125. Genentech, Inc (Roche) Business Overview Table 126. Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 128. Genentech, Inc (Roche) Recent Development Table 129. Ferring Pharmaceuticals Company Information Table 130. Ferring Pharmaceuticals Business Overview Table 131. Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 133. Ferring Pharmaceuticals Recent Development Table 134. EMD Serono Inc. Company Information Table 135. EMD Serono Inc. Business Overview Table 136. EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 138. EMD Serono Inc. Recent Development Table 139. Ascendis Pharma A/S Company Information Table 140. Ascendis Pharma A/S Business Overview Table 141. Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 143. Ascendis Pharma A/S Recent Development Table 144. AnkeBio Co. Ltd Company Information Table 145. AnkeBio Co. Ltd Business Overview Table 146. AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 148. AnkeBio Co. Ltd Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Human Growth Hormone Deficiency (Ghd) Drug Distributors List Table 152. Human Growth Hormone Deficiency (Ghd) Drug Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Human Growth Hormone Deficiency (Ghd) Drug Product Image Figure 2. Global Human Growth Hormone Deficiency (Ghd) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Growth Hormone Deficiency (Ghd) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Growth Hormone Deficiency (Ghd) Drug Sales (2021-2032) & (K Units) Figure 5. Global Human Growth Hormone Deficiency (Ghd) Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Human Growth Hormone Deficiency (Ghd) Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Somavaratan Image Figure 9. Somapacitan Image Figure 10. TransCon-hGH Image Figure 11. Others Image Figure 12. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Type (2021-2032) Figure 15. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Type (2021-2032) Figure 18. Children Image Figure 19. Adults Image Figure 20. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Application (2021-2032) Figure 23. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Country (2021-2032) Figure 28. U.S. Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Country (2021-2032) Figure 33. Germany Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Country (2021-2032) Figure 40. China Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Country (2021-2032) Figure 48. Brazil Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Human Growth Hormone Deficiency (Ghd) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Human Growth Hormone Deficiency (Ghd) Drug Revenue (2021-2032) & (US$ Million) Figure 59. North America Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Human Growth Hormone Deficiency (Ghd) Drug Revenue (2021-2032) & (US$ Million) Figure 61. Europe Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Human Growth Hormone Deficiency (Ghd) Drug Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Human Growth Hormone Deficiency (Ghd) Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Somavaratan
  • Somapacitan
  • TransCon-hGH
  • Others
Applications
  • Children
  • Adults
Companies covered
  • Teva Pharmaceutical Industries, Ltd
  • Merck KGaA
  • Eli Lilly and Company
  • Versartis Inc.
  • Strongbridge Biopharma
  • Sandoz International GmbH (Novartis AG)
  • Pfizer Inc
  • Opko Health, Inc.
  • Novo Nordisk A/S
  • LG Life Sciences
  • Ipsen S.A.
  • GeneScience Pharmaceuticals Co. Ltd
  • Genentech, Inc (Roche)
  • Ferring Pharmaceuticals
  • EMD Serono Inc.
  • Ascendis Pharma A/S
  • AnkeBio Co. Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Growth Hormone Deficiency (Ghd) Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Growth Hormone Deficiency (Ghd) Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Growth Hormone Deficiency (Ghd) Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Growth Hormone Deficiency (Ghd) Drug Market Dynamics
  1. 2.1 Human Growth Hormone Deficiency (Ghd) Drug Industry Trends
  2. 2.2 Human Growth Hormone Deficiency (Ghd) Drug Industry Drivers
  3. 2.3 Human Growth Hormone Deficiency (Ghd) Drug Industry Opportunities and Challenges
  4. 2.4 Human Growth Hormone Deficiency (Ghd) Drug Industry Restraints
3 Human Growth Hormone Deficiency (Ghd) Drug Market by Manufacturers
  1. 3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Growth Hormone Deficiency (Ghd) Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Growth Hormone Deficiency (Ghd) Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Growth Hormone Deficiency (Ghd) Drug Manufacturers, Product Type & Application
  7. 3.7 Global Human Growth Hormone Deficiency (Ghd) Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Growth Hormone Deficiency (Ghd) Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Growth Hormone Deficiency (Ghd) Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Growth Hormone Deficiency (Ghd) Drug Tier 1, Tier 2, and Tier 3
4 Human Growth Hormone Deficiency (Ghd) Drug Market by Type
  1. 4.1 Human Growth Hormone Deficiency (Ghd) Drug Type Introduction
  2. 4.1.1 Somavaratan
  3. 4.1.2 Somapacitan
  4. 4.1.3 TransCon-hGH
  5. 4.1.4 Others
  6. 4.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Type
  7. 4.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Type
  11. 4.3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Type (2021-2032)
5 Human Growth Hormone Deficiency (Ghd) Drug Market by Application
  1. 5.1 Human Growth Hormone Deficiency (Ghd) Drug Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adults
  4. 5.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Application
  5. 5.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Application
  9. 5.3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Application (2021-2032)
6 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region
  1. 6.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Growth Hormone Deficiency (Ghd) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Region
  1. 7.1 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Region
  2. 7.1.1 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Growth Hormone Deficiency (Ghd) Drug Revenue (2021-2032)
  8. 7.2.2 North America Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Growth Hormone Deficiency (Ghd) Drug Revenue (2021-2032)
  11. 7.3.2 Europe Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries, Ltd
  2. 8.1.1 Teva Pharmaceutical Industries, Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries, Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries, Ltd Recent Developments
  7. 8.2 Merck KGaA
  8. 8.2.1 Merck KGaA Company Information
  9. 8.2.2 Merck KGaA Business Overview
  10. 8.2.3 Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  12. 8.2.5 Merck KGaA Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 Versartis Inc.
  20. 8.4.1 Versartis Inc. Company Information
  21. 8.4.2 Versartis Inc. Business Overview
  22. 8.4.3 Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  24. 8.4.5 Versartis Inc. Recent Developments
  25. 8.5 Strongbridge Biopharma
  26. 8.5.1 Strongbridge Biopharma Company Information
  27. 8.5.2 Strongbridge Biopharma Business Overview
  28. 8.5.3 Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  30. 8.5.5 Strongbridge Biopharma Recent Developments
  31. 8.6 Sandoz International GmbH (Novartis AG)
  32. 8.6.1 Sandoz International GmbH (Novartis AG) Company Information
  33. 8.6.2 Sandoz International GmbH (Novartis AG) Business Overview
  34. 8.6.3 Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  36. 8.6.5 Sandoz International GmbH (Novartis AG) Recent Developments
  37. 8.7 Pfizer Inc
  38. 8.7.1 Pfizer Inc Company Information
  39. 8.7.2 Pfizer Inc Business Overview
  40. 8.7.3 Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  42. 8.7.5 Pfizer Inc Recent Developments
  43. 8.8 Opko Health, Inc.
  44. 8.8.1 Opko Health, Inc. Company Information
  45. 8.8.2 Opko Health, Inc. Business Overview
  46. 8.8.3 Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  48. 8.8.5 Opko Health, Inc. Recent Developments
  49. 8.9 Novo Nordisk A/S
  50. 8.9.1 Novo Nordisk A/S Company Information
  51. 8.9.2 Novo Nordisk A/S Business Overview
  52. 8.9.3 Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  54. 8.9.5 Novo Nordisk A/S Recent Developments
  55. 8.10 LG Life Sciences
  56. 8.10.1 LG Life Sciences Company Information
  57. 8.10.2 LG Life Sciences Business Overview
  58. 8.10.3 LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  60. 8.10.5 LG Life Sciences Recent Developments
  61. 8.11 Ipsen S.A.
  62. 8.11.1 Ipsen S.A. Company Information
  63. 8.11.2 Ipsen S.A. Business Overview
  64. 8.11.3 Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  66. 8.11.5 Ipsen S.A. Recent Developments
  67. 8.12 GeneScience Pharmaceuticals Co. Ltd
  68. 8.12.1 GeneScience Pharmaceuticals Co. Ltd Company Information
  69. 8.12.2 GeneScience Pharmaceuticals Co. Ltd Business Overview
  70. 8.12.3 GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  72. 8.12.5 GeneScience Pharmaceuticals Co. Ltd Recent Developments
  73. 8.13 Genentech, Inc (Roche)
  74. 8.13.1 Genentech, Inc (Roche) Company Information
  75. 8.13.2 Genentech, Inc (Roche) Business Overview
  76. 8.13.3 Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  78. 8.13.5 Genentech, Inc (Roche) Recent Developments
  79. 8.14 Ferring Pharmaceuticals
  80. 8.14.1 Ferring Pharmaceuticals Company Information
  81. 8.14.2 Ferring Pharmaceuticals Business Overview
  82. 8.14.3 Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  84. 8.14.5 Ferring Pharmaceuticals Recent Developments
  85. 8.15 EMD Serono Inc.
  86. 8.15.1 EMD Serono Inc. Company Information
  87. 8.15.2 EMD Serono Inc. Business Overview
  88. 8.15.3 EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  90. 8.15.5 EMD Serono Inc. Recent Developments
  91. 8.16 Ascendis Pharma A/S
  92. 8.16.1 Ascendis Pharma A/S Company Information
  93. 8.16.2 Ascendis Pharma A/S Business Overview
  94. 8.16.3 Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  96. 8.16.5 Ascendis Pharma A/S Recent Developments
  97. 8.17 AnkeBio Co. Ltd
  98. 8.17.1 AnkeBio Co. Ltd Company Information
  99. 8.17.2 AnkeBio Co. Ltd Business Overview
  100. 8.17.3 AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  102. 8.17.5 AnkeBio Co. Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Growth Hormone Deficiency (Ghd) Drug Value Chain Analysis
  2. 9.1.1 Human Growth Hormone Deficiency (Ghd) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Growth Hormone Deficiency (Ghd) Drug Production Mode & Process
  6. 9.2 Human Growth Hormone Deficiency (Ghd) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Growth Hormone Deficiency (Ghd) Drug Distributors
  9. 9.2.3 Human Growth Hormone Deficiency (Ghd) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst